FindTrial
Sign In

An Investigator initiated study comparing of two antifungals Anidulafungin and Caspofungin in patients with Invasive Candida Infections

A prospective, observational, open label study to evaluate efficacy and safety of Anidulafungin in comparison to Caspofungin in Invasive Candida infections in India (ADVANCE)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/09/037013
Enrollment
180
Registered
2021-09-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B377- Candidal sepsis

Interventions

None listed

Sponsors

Dr Yatin Mehta
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex with age >=18 years with a confirmed cases of Invasive Candida infection. 2. Patients who will be able to provide the informed consent. 3. Patients prescribed with Caspofungin or Anidulafungin

Exclusion criteria

Exclusion criteria: 1. Patients of either sex with age less than 18 years. 2. Patients with aspergillus or any other mold or yeast [Cryptococcus] infections. 3. Patients on Micafungin or other antifungal agents. 4. Pregnant or breast-feeding women

Design outcomes

Primary

MeasureTime frame
To evaluate and compare the efficacy and safety of Anidulafungin and Caspofungin in Invasive Candida infections in ICUs.Timepoint: Day 1 to Day 14—

Secondary

MeasureTime frame
To determine the distribution pattern of co-morbidities and risk factors for Invasive Candida infectionTimepoint: Day 1 to Day 14;To determine the duration of treatment, number of hospital days and mortality of patients with Invasive Candida Infection.Timepoint: Day 1 to Day 14;To assess the clinical signs and symptoms, baseline candida pathogen, candida scoresTimepoint: Day 1 to Day 14;To assess liver and renal functioning.Timepoint: Day 1 to Day 14—

Countries

India

Contacts

Public ContactDr Yatin Mehta

Medanta The Medicity

yatin.mehta@medanta.org01244141414

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026